1. Al Thani, H, El-Menyar, A, Alhabib, KF, et al. Polyvascular disease in patients presenting with acute coronary syndrome: its predictors and outcomes. ScientificWorldJournal 2012; 2012: 284851.
Google Scholar | Crossref | Medline2. van der Meer, MG, Cramer, MJ, van der Graaf, Y, et al. The impact of polyvascular disease on long-term outcome in percutaneous coronary intervention patients. Eur J Clin Invest 2014; 44: 231–239.
Google Scholar | Crossref | Medline3. Calvet, D, Touze, E, Varenne, O, et al. Prevalence of asymptomatic coronary artery disease in ischemic stroke patients: the PRECORIS study. Circulation 2010; 121: 1623–1629.
Google Scholar | Crossref | Medline4. Gunnoo, T, Hasan, N, Khan, MS, et al. Quantifying the risk of heart disease following acute ischaemic stroke: a meta-analysis of over 50,000 participants. BMJ Open 2016; 6: e9535.
Google Scholar | Crossref | Medline5. Adams, RJ, Chimowitz, MI, Alpert, JS, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke 2003; 34: 2310–2322.
Google Scholar | Medline6. Touze, E, Varenne, O, Chatellier, G, et al. Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis. Stroke 2005; 36: 2748–2755.
Google Scholar | Crossref | Medline7. Roffi, M, Patrono, C, Collet, JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267–315.
Google Scholar | Crossref | Medline8. Steg, PG, James, SK, Atar, D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–2619.
Google Scholar | Crossref | Medline9. Lee, JH, Yang, DH, Park, HS, et al. Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea Acute Myocardial Infarction Registry: prescription rate, predictors, and prognostic value. Am Heart J 2010; 159: 1012–1019.
Google Scholar | Crossref | Medline10. D’Ascenzo, F, Abu-Assi, E, Raposeiras-Roubin, S, et al. BleeMACS: rationale and design of the study. J Cardiovasc Med 2016; 17: 744–749.
Google Scholar | Crossref11. Haraguchi, Y, Sakakura, K, Yamamoto, K, et al. Determinants of insufficient optimal medical therapy after acute myocardial infarction. Intern Med 2020; 59: 1489–1495.
Google Scholar | Crossref | Medline12. Yan, AT, Yan, RT, Tan, M, et al. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J 2007; 154: 1108–1115.
Google Scholar | Crossref | Medline13. Granger, CB, Goldberg, RJ, Dabbous, O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163: 2345–2353.
Google Scholar | Crossref | Medline14. Alexander, KP, Newby, LK, Cannon, CP, et al. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007; 115: 2549–2569.
Google Scholar | Crossref | Medline15. Al, SJ, Reddan, DN, Williams, K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002; 106: 974–980.
Google Scholar | Crossref | Medline16. Cakar, MA, Gunduz, H, Vatan, MB, et al. The effect of admission creatinine levels on one-year mortality in acute myocardial infarction. ScientificWorldJournal 2012; 2012: 186495.
Google Scholar | Crossref | Medline17. Sarnak, MJ, Levey, AS, Schoolwerth, AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050–1065.
Google Scholar | Crossref | Medline18. Shlipak, MG, Heidenreich, PA, Noguchi, H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137: 555–562.
Google Scholar | Crossref | Medline19. Washam, JB, Herzog, CA, Beitelshees, AL, et al. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation 2015; 131: 1123–1149.
Google Scholar | Crossref | Medline20. Shlipak, MG, Browner, WS, Noguchi, H, et al. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. Am J Med 2001; 110: 425–433.
Google Scholar | Crossref | Medline21. Sabatine, MS, Giugliano, RP, Keech, AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.
Google Scholar | Crossref | Medline22. Schwartz, GG, Steg, PG, Szarek, M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379: 2097–2107.
Google Scholar | Crossref | Medline23. Mach, F, Baigent, C, Catapano, AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111–188.
Google Scholar | Crossref | Medline24. Guha, K, Allen, CJ, Hartley, A, et al. Ivabradine: a current overview. Curr Clin Pharmacol 2016; 11: 241–249.
Google Scholar | Crossref | Medline